Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA5A | P35218 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 7/20 | 0.36 |
| ▸ | MAOA | P21397 | 7/20 | 0.36 |
| ▸ | MAOB | P27338 | 7/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL733475 | 1.00 | CFTR (0.38) | CFTRCA2CA4CA5ATSHR | |
| SCHEMBL3513000 | 0.74 | GRM4 (0.37) | TSHRGAA | |
| SCHEMBL751484 | 0.72 | GRM4 (0.36) | — | |
| SCHEMBL731005 | 0.72 | GRM4 (0.36) | — | |
| SCHEMBL731654 | 0.72 | TSHR (0.43) | CFTRCA2CA4CA5ATSHR | |
| SCHEMBL749113 | 0.72 | TSHR (0.43) | CFTRCA2CA4CA5ATSHR | |
| SCHEMBL731196 | 0.71 | GRM4 (0.35) | — | |
| SCHEMBL751704 | 0.71 | GRM4 (0.35) | — | |
| SCHEMBL731657 | 0.68 | GRM4 (0.33) | — | |
| SCHEMBL749115 | 0.67 | MEN1 (0.34) | TSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377873-B2 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-02-19 | — | — | US | disclosed |
| US-8138164-B2 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20100317623-A1 | HCV NS3 Protease Inhibitors | MERCK SHARP & DOHME LLC | 2010-12-16 | — | — | US | disclosed |
| US-20100298210-A1 | HCV NS3 Protease Inhibitors | MERCK SHARP & DOHME LLC | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317623-A1 | HCV NS3 Protease Inhibitors | HAVCR2, GTF3C3, CTSC | CFTR 625/4885CA2 4706/4885CA4 4560/4885 |
| US-20100298210-A1 | HCV NS3 Protease Inhibitors | HAVCR2, GTF3C3, CTSC | CFTR 537/4885CA2 4689/4885CA4 4534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.